Amneal Pharmaceuticals (AMRX) earnings per share (EPS)
Amneal Pharmaceuticals (AMRX) reported diluted earnings per share of $0.22 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$0.38. Figures as of 17 Nov 2026, 21:32 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Earnings per share, fiscal 2025
- $0.22
- Growth, 5 years
- −18.5% a year
- Highest on record
- $0.61fiscal 2020
- Lowest on record
- -$2.74fiscal 2019
- Fiscal years on record
- 82018–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Amneal Pharmaceuticals earnings per share (EPS), in more detail
Over the five fiscal years to 2025 diluted earnings per share shrank at a compound 18.5% a year. Across the 8 fiscal years on record (2018–2025), the highest was $0.61 in fiscal 2020 and the lowest -$2.74 in fiscal 2019.
Earnings per share by fiscal year
Amneal Pharmaceuticals earnings per share (EPS), year by year
| Fiscal year | Earnings per share | Change | Year ended |
|---|---|---|---|
| 2025 | $0.22 | — | |
| 2024 | -$0.38 | — | |
| 2023 | -$0.48 | — | |
| 2022 | -$0.86 | 1,328.6% down | |
| 2021 | $0.07 | 88.5% down | |
| 2020 | $0.61 | — | |
| 2019 | -$2.74 | — | |
| 2018 | -$0.16 | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.
How to read it
It shows how much profit stands behind each share, so it rises when profit grows or when buybacks shrink the share count.
Earnings per share at health care companies of similar size
| Company | Earnings per share | Fiscal year |
|---|---|---|
| Cytokinetics CYTK | -$6.54 | 2025 |
| ABIVAX ABVX | -€4.83 | 2025 |
| Bausch + Lomb BLCO | -$1.02 | 2025 |
| Amneal Pharmaceuticals AMRX | $0.22 | 2025 |
| Caris Life Sciences CAI | -$3.22 | 2025 |
| Immunovant IMVT | -$2.77 | 2026 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Amneal Pharmaceuticals, figure by figure
- Amneal Pharmaceuticals market cap
- Amneal Pharmaceuticals revenue
- Amneal Pharmaceuticals earnings
- Amneal Pharmaceuticals P/E ratio
- Amneal Pharmaceuticals P/S ratio
- Amneal Pharmaceuticals P/B ratio
- Amneal Pharmaceuticals free cash flow
- Amneal Pharmaceuticals operating margin
- Amneal Pharmaceuticals dividend
- Amneal Pharmaceuticals shares outstanding
- Amneal Pharmaceuticals total debt
- Amneal Pharmaceuticals cash on hand
- Amneal Pharmaceuticals total assets
- Amneal Pharmaceuticals return on equity (ROE)
- Amneal Pharmaceuticals return on invested capital (ROIC)
Amneal Pharmaceuticals (AMRX) overview: price, valuation and scorecardAll health care companies by market value
Amneal Pharmaceuticals earnings per share (EPS): questions and answers
What is Amneal Pharmaceuticals's diluted earnings per share?
Amneal Pharmaceuticals (AMRX) reported diluted earnings per share of $0.22 in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$0.38.
What is the growth rate of Amneal Pharmaceuticals's diluted earnings per share?
Over the five fiscal years to 2025 diluted earnings per share shrank at a compound 18.5% a year.
What are the highest and lowest diluted earnings per share figures on record for Amneal Pharmaceuticals?
Across the 8 fiscal years on record (2018–2025), the highest was $0.61 in fiscal 2020 and the lowest -$2.74 in fiscal 2019.
How is Amneal Pharmaceuticals's diluted earnings per share calculated?
Earnings per share is net income divided by the diluted number of shares, as the company reports it; older years are re-based for later stock splits.
Fiscal years are named for the calendar year they end in.
Learn: earnings per share (EPS)
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Amneal Pharmaceuticals (AMRX) earnings per share (EPS)”, data as of 17 November 2026. https://funkfolio.com/stock/AMRX/eps
Underlying data: the company's filings with the SEC and Yahoo Finance.